Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
You can also access detailed information by clicking Login in the website header.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
Germany
Regulatory Approval:
Your Trustedworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Jaypirca (pirtobrutinib) is the first and only non-covalent, reversible Bruton tyrosine kinase (BTK) inhibitor approved for patients whose disease has progressed on a prior covalent BTK inhibitor.
Jaypirca is FDA-approved for adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two prior lines of systemic therapy, including a BTK inhibitor, and for adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) previously treated with a covalent BTK inhibitor.
Unlike covalent BTK inhibitors, pirtobrutinib binds BTK reversibly, allowing it to remain effective against certain resistance mutations that cause treatment failure with first-generation covalent BTK inhibitors.
The recommended dose is 200 mg orally once daily, with or without food, until disease progression or unacceptable toxicity, as determined by the treating hematologist-oncologist.
Jaypirca requires monitoring for several important safety considerations.
Serious and fatal infections, including opportunistic infections such as Pneumocystis jirovecii pneumonia, have occurred. Monitor for signs of infection and consider prophylaxis as clinically indicated.
Serious and fatal bleeding events can occur, with increased risk in patients on concurrent antithrombotic agents. Monitor for signs of bleeding.
Neutropenia, thrombocytopenia, and anemia are common. Monitor complete blood counts regularly throughout treatment.
Monitor for signs and symptoms of arrhythmia; obtain ECG as clinically indicated.
Second primary cancers, including skin cancers, have been reported. Monitor patients for new malignancies.
Monitor liver function tests periodically during treatment.
Jaypirca can cause fetal harm. Effective contraception is required during treatment and for a defined period after the final dose.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Jaypirca (pirtobrutinib) received FDA approval in January 2023 and is manufactured by Eli Lilly, as the first non-covalent BTK inhibitor approved for BTK-inhibitor-experienced patients.
Import of Jaypirca through a Named Patient Program requires a valid prescription from the treating hematologist-oncologist, confirmation of diagnosis and prior BTK inhibitor treatment history, and supporting clinical documentation as required by Indian regulatory authorities.
NPP sources Jaypirca directly from Eli Lilly's authorized supply chain to ensure product authenticity and regulatory compliance.
Jaypirca is sourced through verified, GDP-compliant channels from Eli Lilly's authorized supply chain to ensure authenticity and quality.
Jaypirca tablets should be stored at 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F to 86°F).
Once sourced, Jaypirca is packed and transported under appropriate temperature-controlled conditions to preserve product integrity throughout the import process, with tracking and updates provided at each stage of delivery to the patient or treating hospital in India.
Patients across India can access Jaypirca through NPP's regulated import pathway, with hematology-oncology specialists in major cities supporting the treatment process.
Leading hematology-oncology centers in Mumbai support MCL and CLL/SLL diagnosis and treatment coordination for Jaypirca access.
Delhi's major cancer hospitals assist patients with diagnostic confirmation and prescription support for Jaypirca.
Bangalore's oncology network offers access to lymphoma and leukemia treatment planning for eligible patients.
Chennai-based specialists coordinate Jaypirca access alongside comprehensive lymphoma and leukemia care.
Hyderabad's cancer care institutions support patients pursuing Jaypirca therapy.
Kolkata's oncology centers help coordinate documentation and treatment access for Jaypirca.
Pune-based hematologists assist with diagnosis confirmation and Jaypirca treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Jaypirca.
Kochi's oncology units assist patients with the documentation needed for Jaypirca access.
Chandigarh's cancer care centers support Jaypirca treatment coordination for patients from North India.
Jaipur's oncology specialists help patients navigate the Jaypirca access process.
Lucknow-based cancer centers assist patients pursuing Jaypirca therapy.
Bhubaneswar's oncology institutions support access to Jaypirca for eligible patients.
Guwahati's specialists help coordinate Jaypirca access for patients across the Northeast.
Patients in other cities across India can also access Jaypirca through NPP's nationwide coordination network.
Written By: Nitin Goswami, Senior Medical Content Writer
Last Updated: 10 September 2026
Sources: FDA • CDSCO
Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Last Updated: 10 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
